Holen Sie sich die Stockscreener-App
7.425
6.01%
0.435
Schlusskurs vom Vortag:
$6.99
Offen:
$7
24-Stunden-Volumen:
671.19K
Relative Volume:
0.80
Marktkapitalisierung:
$319.75M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.8066
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+5.26%
1M Leistung:
+19.71%
6M Leistung:
+105.83%
1J Leistung:
-23.05%
1-Tages-Spanne:
$6.94
$7.44
1-Wochen-Bereich:
$6.85
$8.12
52-Wochen-Spanne:
$2.10
$13.52
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Vergleichen Sie VSTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.4353 | 319.75M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.00 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.47 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.54 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.48 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.20 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
It would be worthwhile to take a closer look at Verastem Inc (VSTM) - uspostnews.com
Analyze Verastem Inc (NASDAQ: VSTM) Before Investing. - Stocksregister
Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC - Defense World
Verastem Oncology rises on $75M private placement - MSN
Verastem Oncology secures $75 million in private placement By Investing.com - Investing.com India
Verastem Inc [VSTM] Shares Rise 5.34 % on Thursday - knoxdaily.com
Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold - Endpoints News
Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million - marketscreener.com
Verastem Announces $75M Private Placement Agreement - TipRanks
Verastem Oncology Announces $75 million Private Placement | VSTM Stock News - GuruFocus
Verastem Oncology Announces $75 million Private Placement - Bluefield Daily Telegraph
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
12-Month Price Target For Verastem Inc (NASDAQ:VSTM) Now Sits At 14 - Marketing Sentinel
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors - BioSpace
Verastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375 - GuruFocus
Verastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA A - GuruFocus
Verastem Oncology to initiate trial for its targeted cancer therapy (VSTM:NASDAQ) - Seeking Alpha
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral - GuruFocus
FDA clears Verastem’s new drug for clinical trial By Investing.com - Investing.com Canada
There is no way Verastem Inc (VSTM) can keep these numbers up - Sete News
(VSTM) Trading Report - news.stocktradersdaily.com
Verastem Oncology to Report Q1 Earnings: What's in the Cards? - MSN
Verastem Inc (VSTM) rating initates by Jefferies - knoxdaily.com
Was there any good news for Verastem Inc (VSTM) stock in the last session? - uspostnews.com
Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Jefferies Initiates Coverage of Verastem (LSE:0LOV) with Buy Recommendation - Nasdaq
Verastem (VSTM): Jefferies Initiates Coverage with Buy Rating Am - GuruFocus
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (NASDAQ:VSTM) - Seeking Alpha
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Jefferies Initiates Verastem at Buy With $15 Price Target - marketscreener.com
Jefferies Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
Verastem stock initiated Buy at Jefferies (VSTM:NASDAQ) - Seeking Alpha
Verastem (VSTM) Receives Buy Rating from Jefferies with Promisin - GuruFocus
Jefferies sets $15 price target on Verastem stock with Buy rating - Investing.com Canada
Verastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating - marketscreener.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem Oncology's Strategic Move: 247K Share Package Ties New Talent to Sales Goals - Stock Titan
Where are the Opportunities in (VSTM) - news.stocktradersdaily.com
Verastem Oncology Reports Progress in Cancer Treatments - TipRanks
Verastem, Inc. (NASDAQ:VSTM) Short Interest Update - Defense World
Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat
Bank of New York Mellon Corp Has $457,000 Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire
Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India
Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia
H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verastem Inc-Aktie (VSTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer |
Mar 24 '25 |
Sale |
7.04 |
26 |
183 |
86,348 |
| Paterson Dan | President and CEO |
Mar 17 '25 |
Sale |
6.95 |
244 |
1,696 |
346,479 |
| Gagnon Robert E. | Director |
Mar 17 '25 |
Sale |
6.95 |
284 |
1,974 |
34,193 |
| Stuglik Brian M | Director |
Mar 17 '25 |
Sale |
6.95 |
593 |
4,121 |
94,587 |
| Paterson Dan | President and CEO |
Feb 04 '25 |
Sale |
5.70 |
858 |
4,891 |
346,723 |
| Paterson Dan | President and CEO |
Jan 13 '25 |
Sale |
5.24 |
8,568 |
44,896 |
347,581 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):